Track record
Every buy, sell, and watch call I've published — scored against XBI, the biotech index.
As of Aug 21, 2026 · hypothetical editorial record, not investment advice
How to read this page
- Buy
- A buy call I published — Core = higher conviction.
- Spec buy
- A speculative buy — higher risk, smaller-size idea.
- Avoid
- A call to stay away — scored by the loss it sidestepped.
- Entry
- The stock's closing price the day I published the call.
- Now
- The latest available closing price.
- Return
- Percent change from Entry to Now (for avoids, the stock's move since the call).
- vs XBI
- XBI is the biotech index ETF. This is Return minus XBI's return over the same dates — the value added beyond just buying the index. For avoids, the loss saved vs holding XBI.
- Open / Closed
- Open = still live. Closed = realized; I flipped the call, calculated return based on that date.
Top buy calls
| Call | Buy | Now | Return | vs XBI |
|---|---|---|---|---|
| ETON Eton Pharmaceuticals Buy | $18.22 | $63.47 | +248.4% | +217.6 |
| SYRE Spyre Therapeutics Buy | $33.47 | $106.49 | +218.2% | +179.6 |
| DFTX Definium Therapeutics Buy | $15.02 | $44.91 | +199% | +168.3 |
| IBRX ImmunityBio Buy | $3.02 | $7.79 | +157.9% | +127.3 |
| DRTS Alpha Tau Medical Spec buy | $5.90 | $14.92 | +152.9% | +121.8 |
| ADAG Adagene Spec buy | $1.84 | $4.02 | +118.5% | +82.1 |
| HELP Cybin Spec buy | $6.88 | $12.59 | +83% | +78.3 |
| CLYM Climb Bio Buy | $8.78 | $17.28 | +96.8% | +68.2 |
| CRDL Cardiol Therapeutics Spec buy | $1.02 | $1.86 | +82.4% | +51.4 |
| ORKA Oruka Therapeutics Buy | $63.18 | $107.96 | +70.9% | +48.9 |
What I told you to avoid
| Call | Since | Stock | Saved vs XBI |
|---|---|---|---|
| RVPH Reviva Pharmaceuticals Avoid | Jan 26, 2026 | -92% | +121.7 |
| APVO Aptevo Therapeutics Avoid | Jun 16, 2026 | -41% | +63.4 |
| NRSN NeuroSense Therapeutics Avoid | Jul 13, 2026 | -48.5% | +55.2 |
| VNDA Vanda Pharmaceuticals Avoid | Feb 17, 2026 | -14.8% | +47.8 |
| MRKR Marker Therapeutics Avoid | Mar 16, 2026 | -1.4% | +35.2 |
| IXHL Incannex Healthcare Avoid | Mar 16, 2026 | +7.9% | +25.9 |
| LGVN Longeveron Avoid | May 11, 2026 | +0.8% | +22.2 |
| ACTU Actuate Therapeutics Avoid | Jul 17, 2026 | -11.8% | +19.2 |
Calls that paid off
Buy calls I closed in the green — including takeouts. Entry → exit, realized.
| Call | Bought | Exited | Return | vs XBI |
|---|---|---|---|---|
| FBRX Forte Biosciences Acquired | Apr 6, 2026 | Jul 28, 2026 | +189.9% | +173.6 |
| CRNX Crinetics Pharmaceuticals Acquired | Apr 2, 2026 | Jul 6, 2026 | +128.3% | +103.6 |
| ATAI Atai Beckley Acquired | Dec 24, 2025 | Jul 16, 2026 | +70.6% | +50.3 |
| APGE Apogee Therapeutics Acquired | May 5, 2026 | Jun 22, 2026 | +59.1% | +50.1 |
| ENTA Enanta Pharmaceuticals Buy | Feb 17, 2026 | Jul 2, 2026 | +9% | -19.7 |
Every call
| Call | Entry | Now | Return | vs XBI | Status | Opened |
|---|---|---|---|---|---|---|
| ETON Eton Pharmaceuticals Buy | $18.22 | $63.47 | +248.4% | +217.6 | Open | Feb 19, 2026 |
| SYRE Spyre Therapeutics Buy | $33.47 | $106.49 | +218.2% | +179.6 | Open | Dec 18, 2025 |
| FBRX Forte Biosciences Buy | $26.44 | $76.65 | +189.9% | +173.6 | Closed Jul 28, 2026 | Apr 6, 2026 |
| DFTX Definium Therapeutics Buy | $15.02 | $44.91 | +199% | +168.3 | Open | Jan 14, 2026 |
| IBRX ImmunityBio Buy | $3.02 | $7.79 | +157.9% | +127.3 | Open | Jan 14, 2026 |
| DRTS Alpha Tau Medical Spec buy | $5.90 | $14.92 | +152.9% | +121.8 | Open | Jan 7, 2026 |
| RVPH Reviva Pharmaceuticals Avoid | $6.04 | $0.48 | -92% | +121.7 | Open | Jan 26, 2026 |
| CRNX Crinetics Pharmaceuticals Buy | $37.23 | $85.00 | +128.3% | +103.6 | Closed Jul 6, 2026 | Apr 2, 2026 |
| GOSS Gossamer Bio Avoid | $0.43 | $0.15 | -63.9%* | +94.8 | Closed Aug 22, 2026 | Mar 2, 2026 |
| ADAG Adagene Spec buy | $1.84 | $4.02 | +118.5% | +82.1 | Open | Jan 2, 2026 |
| HELP Cybin Spec buy | $6.88 | $12.59 | +83% | +78.3 | Open | Jun 29, 2026 |
| CLYM Climb Bio Buy | $8.78 | $17.28 | +96.8% | +68.2 | Open | Apr 29, 2026 |
| APVO Aptevo Therapeutics Avoid | $4.54 | $2.68 | -41% | +63.4 | Open | Jun 16, 2026 |
| ACTU Actuate Therapeutics Avoid | $6.49 | $2.89 | -55.5% | +62.2 | Closed May 12, 2026 | Jan 7, 2026 |
| NRSN NeuroSense Therapeutics Avoid | $0.73 | $0.38 | -48.5% | +55.2 | Open | Jul 13, 2026 |
| CRDL Cardiol Therapeutics Spec buy | $1.02 | $1.86 | +82.4% | +51.4 | Open | Mar 2, 2026 |
| ATAI Atai Beckley Buy | $4.19 | $7.15 | +70.6% | +50.3 | Closed Jul 16, 2026 | Dec 24, 2025 |
| APGE Apogee Therapeutics Buy | $83.29 | $132.55 | +59.1% | +50.1 | Closed Jun 22, 2026 | May 5, 2026 |
| ORKA Oruka Therapeutics Buy | $63.18 | $107.96 | +70.9% | +48.9 | Open | May 13, 2026 |
| REPL Replimune Group Buy | $8.69 | $14.77 | +70% | +48.7 | Open | May 29, 2026 |
| VNDA Vanda Pharmaceuticals Avoid | $6.20 | $5.28 | -14.8% | +47.8 | Open | Feb 17, 2026 |
| GHRS GH Research Buy | $15.75 | $28.33 | +79.9% | +47.6 | Open | Jan 20, 2026 |
| CGEM Cullinan Therapeutics Buy | $12.57 | $21.68 | +72.5% | +46.5 | Open | Jan 22, 2026 |
| CING Cingulate Avoid | $5.84 | $5.09 | -12.8% | +45.4 | Closed Aug 14, 2026 | Mar 30, 2026 |
| TVTX Travere Therapeutics Buy | $40.29 | $65.71 | +63.1% | +42.8 | Open | Apr 20, 2026 |
| NRIX Nurix Therapeutics Buy | $15.91 | $26.72 | +67.9% | +42.4 | Open | Apr 13, 2026 |
| CAPR Capricor Therapeutics Spec buy | $4.17 | $6.29 | +50.8% | +41.7 | Open | Aug 4, 2026 |
| PCSA Processa Pharmaceuticals Avoid | $2.87 | $2.03 | -29.3% | +41.3 | Closed Jul 29, 2026 | Apr 13, 2026 |
| IMVT Immunovant Buy | $26.08 | $44.37 | +70.1% | +40 | Open | Feb 2, 2026 |
| CMPS COMPASS Pathways Buy | $7.85 | $13.33 | +69.8% | +39.3 | Open | Feb 23, 2026 |
| ABSI Absci Buy | $5.90 | $9.55 | +61.9% | +38.8 | Open | May 8, 2026 |
| MRKR Marker Therapeutics Avoid | $1.41 | $1.39 | -1.4% | +35.2 | Open | Mar 16, 2026 |
| VOR Vor Biopharma Spec buy | $14.63 | $23.36 | +59.7% | +32.9 | Open | May 15, 2026 |
| ARTV Artiva Biotherapeutics Spec buy | $6.80 | $10.93 | +60.7% | +31.7 | Open | Jun 8, 2026 |
| IXHL Incannex Healthcare Avoid | $3.31 | $3.57 | +7.9% | +25.9 | Open | Mar 16, 2026 |
| OVID Ovid Therapeutics Spec buy | $1.81 | $2.80 | +54.7% | +25.8 | Open | Jan 27, 2026 |
| DYN Dyne Therapeutics Buy | $16.58 | $26.10 | +57.4% | +25.1 | Open | Jan 20, 2026 |
| LGVN Longeveron Avoid | $0.84 | $0.84 | +0.8% | +22.2 | Open | May 11, 2026 |
| RNAC Cartesian Therapeutics Buy | $6.93 | $10.04 | +44.9% | +21.6 | Open | May 27, 2026 |
| NVCT Nuvectis Pharma Spec buy | $17.55 | $23.56 | +34.2% | +21.5 | Open | Jun 23, 2026 |
| AUTL Autolus Therapeutics Spec buy | $1.82 | $2.41 | +32.4% | +19.9 | Open | Aug 3, 2026 |
| XNCR Xencor Spec buy | $21.49 | $27.80 | +29.4% | +19.9 | Open | Jul 30, 2026 |
| ACTU Actuate Therapeutics Avoid | $1.44 | $1.27 | -11.8% | +19.2 | Open | Jul 17, 2026 |
| CGON CG Oncology Buy | $53.81 | $79.81 | +48.3% | +18.9 | Open | Jan 23, 2026 |
| TTRX Turn Therapeutics Spec buy | $6.42 | $9.46 | +47.4% | +17.6 | Open | Jun 2, 2026 |
| ZYME Zymeworks Spec buy | $23.54 | $28.67 | +21.8% | +16.5 | Open | Aug 7, 2026 |
| NGNE Neurogene Spec buy | $32.18 | $38.63 | +20% | +15.9 | Open | Jun 30, 2026 |
| HELP Cybin Avoid | $5.52 | $4.32 | -21.7% | +15.2 | Closed Mar 30, 2026 | Mar 9, 2026 |
| ACRS Aclaris Therapeutics Buy | $4.47 | $6.41 | +43.4% | +14.8 | Open | Apr 29, 2026 |
| SPRB Spruce Biosciences Spec buy | $41.60 | $51.58 | +24% | +13.3 | Open | Jul 28, 2026 |
| PHIO Phio Pharmaceuticals Avoid | $1.07 | $1.18 | +10.3% | +12.7 | Open | May 8, 2026 |
| KYMR Kymera Therapeutics Buy | $87.35 | $119.80 | +37.1% | +11.4 | Open | Apr 9, 2026 |
| CYDY CytoDyn Avoid | $0.37 | $0.32 | -13.5% | +11.1 | Closed Apr 27, 2026 | Apr 21, 2026 |
| KAPA Kairos Pharma Avoid | $0.31 | $0.29 | -6.5% | +10 | Open | Aug 18, 2026 |
| MDNAF Medicenna Therapeutics Avoid | $0.40 | $0.34 | -14.9% | +8.9 | Closed May 19, 2026 | May 14, 2026 |
| ELTX Elicio Therapeutics Avoid | $3.22 | $3.04 | -5.6% | +8.9 | Open | Jul 2, 2026 |
| ARDX Ardelyx Avoid | $4.00 | $3.89 | -2.7% | +8.1 | Open | Aug 7, 2026 |
| GRCE Grace Therapeutics Avoid | $2.30 | $2.10 | -8.7% | +7.1 | Closed Apr 28, 2026 | Apr 24, 2026 |
| ADCT ADC Therapeutics Avoid | $1.01 | $1.00 | -1.3% | +6.6 | Open | Aug 14, 2026 |
| SLDB Solid Biosciences Spec buy | $8.39 | $9.30 | +10.8% | +5.5 | Open | Aug 7, 2026 |
| BCTX BriaCell Therapeutics Avoid | $3.27 | $4.07 | +24.5% | +5.3 | Open | Jun 2, 2026 |
| IMMX Immix Biopharma Buy | $10.66 | $13.66 | +28.1% | +5.3 | Open | May 12, 2026 |
| CHRS Coherus Oncology Spec buy | $1.26 | $1.42 | +12.3% | +5 | Open | Aug 6, 2026 |
| PEPG PepGen Spec buy | $2.85 | $3.14 | +10.2% | +4.9 | Open | Aug 7, 2026 |
| XERS Xeris Biopharma Spec buy | $7.93 | $8.70 | +9.7% | +4.4 | Open | Aug 7, 2026 |
| ZBIO Zenas BioPharma Spec buy | $29.51 | $32.29 | +9.4% | +4.1 | Open | Aug 14, 2026 |
| ALLO Allogene Therapeutics Spec buy | $1.90 | $2.09 | +10% | +3.9 | Open | Jul 15, 2026 |
| CBIO Crescent Biopharma Buy | $15.67 | $17.15 | +9.4% | +3.4 | Open | Jul 15, 2026 |
| CCCC C4 Therapeutics Buy | $3.17 | $4.00 | +26.2% | +3.3 | Open | May 12, 2026 |
| EVMN Evommune Avoid | $13.79 | $14.02 | +1.6% | +2.5 | Open | Jun 30, 2026 |
| AMLX Amylyx Pharmaceuticals Spec buy | $38.60 | $38.66 | +0.2% | +2.4 | Open | Aug 19, 2026 |
| KURA Kura Oncology Buy | $9.22 | $11.89 | +29% | +2.1 | Open | May 15, 2026 |
| FBIO Fortress Biotech Spec buy | $2.27 | $2.87 | +26.4% | +1.9 | Open | Apr 27, 2026 |
| LEGN Legend Biotech Spec buy | $20.65 | $21.82 | +5.7% | +1.7 | Open | Aug 12, 2026 |
| SION Sionna Therapeutics Avoid | $5.10 | $5.29 | +3.7% | +1.1 | Open | Aug 11, 2026 |
| PYPD PolyPid Spec buy | $4.78 | $5.10 | +6.7% | +1 | Open | Aug 13, 2026 |
| UNCY Unicycive Therapeutics Avoid | $5.13 | $5.63 | +9.7% | +0.4 | Open | Jul 27, 2026 |
| OCS Oculis Holding Spec buy | $11.99 | $13.09 | +9.1% | 0 | Open | Aug 4, 2026 |
| IRD Opus Genetics Spec buy | $3.71 | $4.05 | +9.2% | 0 | Open | Aug 4, 2026 |
| ZNTL Zentalis Pharmaceuticals Spec buy | $3.83 | $3.83 | 0% | 0 | Open | Aug 21, 2026 |
| RCUS Arcus Biosciences Spec buy | $23.86 | $30.34 | +27.2% | -0.5 | Open | Jun 3, 2026 |
| AKTS Aktis Oncology Buy | $19.73 | $24.07 | +22% | -0.8 | Open | May 12, 2026 |
| AGMB Agomab Therapeutics Spec buy | $11.94 | $13.25 | +11% | -1.7 | Open | Jun 23, 2026 |
| EXEL Exelixis Spec buy | $41.36 | $54.08 | +30.8% | -2.1 | Open | Jan 30, 2026 |
| NBP NovaBridge Biosciences Spec buy | $1.96 | $2.00 | +1.9% | -2.2 | Open | Jun 30, 2026 |
| CLDX Celldex Therapeutics Buy | $33.86 | $40.38 | +19.3% | -3.1 | Open | Apr 16, 2026 |
| VSTM Verastem Spec buy | $6.74 | $6.89 | +2.2% | -3.1 | Open | Aug 7, 2026 |
| TENX Tenax Therapeutics Avoid | $1.62 | $1.75 | +8% | -3.2 | Open | Aug 11, 2026 |
| GRCE Grace Therapeutics Spec buy | $2.12 | $2.20 | +3.8% | -3.5 | Open | Aug 6, 2026 |
| CRVO CervoMed Avoid | $2.25 | $2.86 | +27.1% | -4.5 | Closed Aug 10, 2026 | Jun 10, 2026 |
| SANA Sana Biotechnology Spec buy | $3.26 | $3.91 | +19.9% | -4.6 | Open | Apr 27, 2026 |
| RARE Ultragenyx Pharmaceutical Buy | $24.93 | $25.83 | +3.6% | -4.7 | Open | Aug 5, 2026 |
| ARVN Arvinas Spec buy | $9.00 | $9.37 | +4.1% | -5 | Open | Aug 4, 2026 |
| CRVS Corvus Pharmaceuticals Buy | $11.50 | $14.46 | +25.7% | -5 | Open | May 19, 2026 |
| ENTA Enanta Pharmaceuticals Spec buy | $13.50 | $13.47 | -0.2% | -5.1 | Open | Aug 12, 2026 |
| JANX Janux Therapeutics Buy | $14.11 | $17.39 | +23.2% | -5.3 | Open | Apr 29, 2026 |
| SABS SAB Biotherapeutics Spec buy | $3.67 | $3.78 | +3.1% | -5.9 | Open | Jul 16, 2026 |
| NRXP NRX Pharmaceuticals Spec buy | $3.03 | $3.56 | +17.5% | -7.1 | Open | Apr 27, 2026 |
| SGMT Sagimet Biosciences Spec buy | $8.75 | $10.25 | +17.1% | -9.2 | Open | Apr 28, 2026 |
| JBIO Jade Biosciences Spec buy | $17.75 | $21.34 | +20.2% | -9.5 | Open | Jun 2, 2026 |
| PCSA Processa Pharmaceuticals Spec buy | $2.03 | $2.08 | +2.5% | -9.6 | Open | Jul 29, 2026 |
| KPRX Kiora Pharmaceuticals Spec buy | $2.32 | $2.66 | +14.7% | -9.9 | Open | Apr 27, 2026 |
| OMER Omeros Buy | $15.71 | $19.27 | +22.7% | -9.9 | Open | Dec 26, 2025 |
| GERN Geron Spec buy | $1.57 | $1.52 | -3.2% | -10.5 | Open | Aug 6, 2026 |
| PMN ProMIS Neurosciences Spec buy | $14.52 | $14.51 | -0.1% | -10.7 | Open | Jul 28, 2026 |
| LENZ LENZ Therapeutics Spec buy | $5.04 | $4.68 | -7.1% | -11.1 | Open | Aug 12, 2026 |
| QURE uniQure Spec buy | $48.16 | $44.39 | -7.8% | -12.5 | Closed Jun 22, 2026 | Jun 17, 2026 |
| CNTB Connect Biopharma Spec buy | $2.54 | $2.36 | -7.1% | -12.7 | Open | Aug 13, 2026 |
| ELTX Elicio Therapeutics Avoid | $4.08 | $4.71 | +15.4% | -13.2 | Closed Jun 17, 2026 | Jun 15, 2026 |
| ARTV Artiva Biotherapeutics Spec buy | $10.60 | $8.55 | -19.3% | -13.4 | Closed May 19, 2026 | May 11, 2026 |
| GPCR Structure Therapeutics Buy | $43.56 | $49.09 | +12.7% | -13.7 | Open | Apr 28, 2026 |
| ADMA Adma Biologics Avoid | $9.16 | $10.06 | +9.8% | -13.7 | Closed Aug 6, 2026 | Jul 6, 2026 |
| BLTE Belite Bio Spec buy | $178.94 | $161.06 | -10% | -14 | Open | Aug 12, 2026 |
| LGVN Longeveron Spec buy | $0.89 | $0.84 | -5.6% | -14.4 | Closed May 11, 2026 | Mar 16, 2026 |
| BCTX BriaCell Therapeutics Spec buy | $4.47 | $3.76 | -15.9% | -15.6 | Closed Feb 23, 2026 | Feb 2, 2026 |
| ALLO Allogene Therapeutics Spec buy | $2.25 | $2.10 | -6.7% | -16.3 | Closed Jun 22, 2026 | Apr 27, 2026 |
| CATX Perspective Therapeutics Buy | $2.73 | $3.30 | +20.9% | -17.1 | Open | Jan 5, 2026 |
| ATHE Alterity Therapeutics Buy | $4.29 | $4.67 | +8.9% | -17.3 | Open | Jun 9, 2026 |
| HELP Cybin Spec buy | $6.73 | $5.52 | -18% | -18.1 | Closed Mar 9, 2026 | Feb 23, 2026 |
| XENE Xenon Pharmaceuticals Buy | $57.40 | $60.77 | +5.9% | -18.3 | Open | May 4, 2026 |
| ACRV Acrivon Therapeutics Buy | $1.93 | $2.21 | +14.5% | -19.5 | Open | Jan 8, 2026 |
| ABOS Acumen Pharmaceuticals Spec buy | $2.71 | $3.16 | +16.6% | -19.6 | Open | Mar 23, 2026 |
| ENTA Enanta Pharmaceuticals Buy | $13.86 | $15.11 | +9% | -19.7 | Closed Jul 2, 2026 | Feb 17, 2026 |
| COGT Cogent Biosciences Buy | $37.00 | $36.73 | -0.7% | -21 | Open | Apr 20, 2026 |
| MPLT MapLight Therapeutics Spec buy | $12.92 | $11.21 | -13.2% | -21.5 | Open | Aug 5, 2026 |
| ERAS Erasca Spec buy | $11.56 | $9.11 | -21.2% | -24.6 | Closed Apr 29, 2026 | Feb 11, 2026 |
| VIR Vir Biotechnology Buy | $8.99 | $9.78 | +8.8% | -25 | Open | Mar 25, 2026 |
| RYTM Rhythm Pharmaceuticals Buy | $102.59 | $110.00 | +7.2% | -25.1 | Open | Jan 20, 2026 |
| VERA Vera Therapeutics Buy | $31.26 | $32.27 | +3.2% | -26.5 | Open | Jun 2, 2026 |
| TNGX Tango Therapeutics Buy | $24.87 | $23.88 | -4% | -26.9 | Open | May 14, 2026 |
| RCKT Rocket Pharmaceuticals Buy | $3.48 | $3.51 | +0.9% | -27.7 | Open | Apr 29, 2026 |
| NTLA Intellia Therapeutics Spec buy | $13.20 | $12.84 | -2.7% | -29.1 | Open | Apr 28, 2026 |
| SRPT Sarepta Therapeutics Spec buy | $17.79 | $18.79 | +5.6% | -29.3 | Open | Feb 13, 2026 |
| TSHA Taysha Gene Therapies Buy | $6.46 | $6.09 | -5.7% | -30.3 | Open | Apr 27, 2026 |
| KYTX Kyverna Therapeutics Buy | $8.99 | $8.42 | -6.3% | -30.9 | Open | Apr 27, 2026 |
| IPSC Century Therapeutics Spec buy | $2.12 | $2.07 | -2.4% | -31.4 | Open | Jun 8, 2026 |
| CBIO Crescent Biopharma Buy | $18.52 | $15.31 | -17.3% | -32.7 | Closed Jul 14, 2026 | May 11, 2026 |
| MAIA MAIA Biotechnology Spec buy | $1.31 | $1.39 | +6.1% | -33.4 | Open | Mar 30, 2026 |
| BMEA Biomea Fusion Spec buy | $1.53 | $1.37 | -10.5% | -36.8 | Open | Apr 28, 2026 |
| ARVN Arvinas Spec buy | $10.78 | $7.74 | -28.2% | -37.5 | Closed Jun 22, 2026 | May 4, 2026 |
| CRBU Caribou Biosciences Spec buy | $1.94 | $1.66 | -14.4% | -37.5 | Open | May 8, 2026 |
| MDNAF Medicenna Therapeutics Spec buy | $0.33 | $0.29 | -11.8% | -37.7 | Open | May 22, 2026 |
| ANAB AnaptysBio Spec buy | $66.59 | $57.74 | -13.3% | -37.9 | Open | Apr 27, 2026 |
| CGTX Cognition Therapeutics Spec buy | $1.08 | $1.00 | -7.8% | -38.2 | Open | Mar 9, 2026 |
| VKTX Viking Therapeutics Buy | $36.41 | $33.89 | -6.9% | -39.6 | Open | Dec 23, 2025 |
| GLUE Monte Rosa Therapeutics Buy | $17.50 | $14.30 | -18.3% | -40.4 | Open | Apr 14, 2026 |
| VTVT vTv Therapeutics Spec buy | $36.41 | $33.26 | -8.7% | -40.9 | Open | Feb 4, 2026 |
| OCGN Ocugen Spec buy | $1.65 | $1.39 | -15.8% | -41.7 | Open | Jan 22, 2026 |
| CABA Cabaletta Bio Buy | $3.83 | $3.13 | -18.3% | -42.4 | Open | May 4, 2026 |
| GRCE Grace Therapeutics Spec buy | $3.83 | $2.30 | -39.9% | -44.2 | Closed Apr 24, 2026 | Jan 26, 2026 |
| AKBA Akebia Therapeutics Spec buy | $1.16 | $0.91 | -21.8% | -44.8 | Open | May 8, 2026 |
| CUE Cue Biopharma Spec buy | $28.62 | $23.98 | -16.2% | -45.9 | Open | Jun 2, 2026 |
| DBVT DBV Technologies Buy | $20.27 | $14.86 | -26.7% | -47.4 | Closed Jul 16, 2026 | Dec 22, 2025 |
| CLNN Clene Buy | $5.18 | $4.32 | -16.6% | -50.3 | Open | Jan 12, 2026 |
| SMMT Summit Therapeutics Buy | $15.94 | $13.16 | -17.4% | -50.3 | Open | Feb 20, 2026 |
| IMTX Immatics Buy | $10.45 | $8.93 | -14.5% | -50.9 | Open | Jan 2, 2026 |
| LRMR Larimar Therapeutics Buy | $5.23 | $4.18 | -20.1% | -51 | Open | Mar 2, 2026 |
| GLSI Greenwich LifeSciences Spec buy | $23.67 | $16.67 | -29.6% | -53.8 | Open | Jun 4, 2026 |
| VRDN Viridian Therapeutics Buy | $29.17 | $24.29 | -16.7% | -54 | Open | Feb 5, 2026 |
| IMRX Immuneering Spec buy | $6.66 | $5.30 | -20.4% | -54.7 | Open | Dec 29, 2025 |
| CYDY CytoDyn Spec buy | $0.32 | $0.21 | -34.4% | -58.9 | Open | Apr 27, 2026 |
| KTTA Pasithea Therapeutics Buy | $0.77 | $0.54 | -30% | -59.8 | Open | May 18, 2026 |
| INAB IN8bio Spec buy | $1.56 | $0.98 | -37.2% | -60.4 | Closed Aug 7, 2026 | Jun 2, 2026 |
| ALT Altimmune Buy | $4.09 | $3.11 | -24% | -61.9 | Open | Jan 5, 2026 |
| STRO Sutro Biopharma Buy | $33.59 | $21.04 | -37.4% | -61.9 | Open | Apr 27, 2026 |
| CTMX CytomX Therapeutics Spec buy | $4.46 | $3.28 | -26.5% | -62.6 | Open | Mar 23, 2026 |
| BIOA BioAge Labs Buy | $15.34 | $9.48 | -38.2% | -68 | Open | May 18, 2026 |
| GANX Gain Therapeutics Buy | $3.19 | $2.00 | -37.1% | -68.8 | Open | Dec 22, 2025 |
| LXEO Lexeo Therapeutics Spec buy | $8.12 | $4.88 | -39.9% | -73.6 | Open | Jan 12, 2026 |
| ERAS Erasca Avoid | $9.11 | $17.90 | +96.5% | -76 | Closed Jul 13, 2026 | Apr 29, 2026 |
| NGEN NervGen Pharma Spec buy | $3.85 | $1.86 | -51.7% | -76.3 | Open | Apr 27, 2026 |
| REPL Replimune Group Avoid | $4.76 | $8.69 | +82.6% | -77 | Closed May 29, 2026 | Apr 10, 2026 |
| TARA Protara Therapeutics Spec buy | $7.43 | $3.85 | -48.2% | -78.7 | Open | Feb 23, 2026 |
| EYPT EyePoint Buy | $13.34 | $5.32 | -60.1% | -87.2 | Open | May 1, 2026 |
| MIST Milestone Pharmaceuticals Buy | $2.35 | $1.05 | -55% | -90.4 | Open | Dec 15, 2025 |
| GUTS Fractyl Health Spec buy | $2.09 | $0.78 | -62.7% | -93.8 | Open | Jan 7, 2026 |
| WVE Wave Life Sciences Buy | $13.44 | $5.29 | -60.6% | -94.8 | Open | Mar 3, 2026 |
| QURE uniQure Avoid | $17.99 | $48.16 | +167.7% | -158.1 | Closed Jun 17, 2026 | Mar 9, 2026 |
No calls match these filters.
On my watch list
-
Elite molluscum data and a clean common-warts competitive setup are offset by a going-concern balance sheet that cannot reach the mid-2027 catalyst on committed capital, a ~$13M shelf ceiling, and a Chairman holding a first lien plus a 16% IRR catch-up that triggers on commercial success.
- ACIU AC Immune Watch
ACI-19764 cleared first-in-human with confirmed CSF penetration, dose-dependent IL-1β inhibition, and a 4x lower-than-predicted therapeutic dose, upgrading the second shot on goal, but VacSYn week-100 remains the decisive catalyst and no owned asset has efficacy data.
-
Q3 European revenue of $8,700 on 750 units with product expiring in the channel is the first hard commercial data point and it points the wrong way, challenging the entire U.S. ramp thesis while going-concern language survives even the $55M raise.
-
Strong biology and productive platform, but Lineage owns only ~half the economics of a lead asset it does not control on a timeline it cannot influence; revisit only on Roche's public disclosure of intent to advance OpRegen into a controlled multicenter Phase 2/3.
-
Cash compressed to $10.8M with burn accelerating, going-concern language unchanged, and the pivotal POC 1 placebo-controlled unblinding conspicuously absent from the update, while the stock has rallied 32.9% on regulatory paperwork — making current levels the least favorable entry point in the cycle.
- PMVP PMV Pharmaceuticals Watch
Auditors issued a formal going-concern warning with $79.4M cash and ~$17M/quarter burn, but PYNNACLE enrollment is complete and the market cap trades below cash; the stance stays Watch until the financing event resolves the capital structure.
-
The $150M ATM bridges the structural dilution gap and de-links launch spending from the approval-triggered warrant clock, but the Sopharma arbitration and NCE exclusivity question remain unresolved, keeping the stock uninvestable.
- NKTR Nektar Therapeutics Watch
Q2 cash of $1.02B is positive but management's Q3-2028 runway guide creates a dilution countdown that barely clears the mid-2028 ZENITH topline, reinforcing the wait-for-better-entry case for new money.
- KOD Kodiak Sciences Hold
Cash down to $125.9M with going-concern language still present and burn accelerating as a third Phase 3 (ALTO) launches; a capital raise is the most predictable unannounced event on the calendar, and DAYBREAK in September gates everything — BLA, platform thesis, and financing terms.
- GNLX Genelux Watch
Q2 burn accelerated to $9.6M against $18.7M total cash with the Phase 3 topline still guided to 2H 2026, tightening the runway squeeze but leaving the scientific thesis and watch-list stance unchanged.
-
Science unchanged but funding quality weakened — burn not moderating at ~$70M/quarter, ATM issuance tripling, and IP pledged as collateral on Hercules debt; thesis still resolves at Q2 2027 4FRONT-1 readout.
-
Despite compelling mechanism and tolerability data, the Phase 2 missed its primary endpoint, the Phase 3 NI margin is undisclosed, and the trial is unfunded against a going-concern conclusion, making the risk/reward insufficient to open a position.
- EIKN Eikon Therapeutics Watch
Resolution of the Seven and Eight licensor dispute removes a key tail risk, but accelerating burn (77% YoY) widens the dilution gap and no efficacy data has changed; the randomized melanoma interim remains the sole re-rating trigger.
-
WATCH maintained with downgraded urgency as 39.6M warrants at $2.65 are now exercisable creating a structural ceiling, NDA slipped to mid-2027, and another financing raise is likely before the key catalyst.
- SCYX Scynexis Watch
Adage Capital's 9.99% filing narrows the sponsorship gap in the bear case, but with ~half the position in deep-OTM warrants and no human ADPKD efficacy, the stance remains Watch with piqued interest.
- INSM Insmed Watch
Elite BRINSUPRI launch is already priced at 15-17x forward revenue; TPIP carries $6B of the peak estimate with no Phase 3 data, no readout for 18+ months, and an approved dry-powder competitor already taking share — may move to Buy if a Q4 2026/Q1 2027 print confirms 12-month persistence.
- ANNX Annexon Watch
ARCHER II adds Month 24 dual primary endpoint meaning Q4 2026 delivers only a DMC verdict with full data potentially in Q1 2027; catalyst diffusion and $117.8M ATM overhead keep the stock on watch despite improved GBS outlook and runway extended into 2028.
- ZURA Zura Bio Watch
Naming PMR as the third indication — where both IL-17 and B-cell arms have randomized clinical support — narrows the bear case modestly, but the BAFF contribution in HS remains unproven and Q4 2026 remains a binary with the stock more than tripled off its lows.
-
REGAL still at 78/80 events after three months of silence; readout timing now indefinite; stock at $11 with doubled downside risk vs. May; fortress balance sheet intact but premium for the binary has a time cost; watch for existing holders to consider trimming.
-
IZAR-1 Phase 3 win de-risks the PsA franchise but the de-risking event remains the Section 14 label content at BLA acceptance in late November 2026; the blinded placebo arm keeps the PsA delta unpriceable.
- IMUX Immunic Watch
Watch list maintained as runway is now explicitly bridged to late 2027 and the commercial/regulatory team is complete, but fenebrutinib, generic Aubagio, the 5% royalty stack, and dilution overhang are unchanged, and the stock at $15.48 has compressed the pre-data asymmetry considerably.
- IMNM Immunome Watch
FDA acceptance with April 2027 PDUFA date is procedurally de-risking but EV expanded to ~$2.5B on a standard review timeline, stretching valuation further while commercial risk is time-amplified by nine more months of incumbent entrenchment.
-
Solvency risk is retired with $62M cash and runway into mid-2028, but zero new human efficacy data, Phase 2b slipped a quarter, and the stock is up 37% since June on balance sheet re-rating alone — the entry point has worsened without any improvement in probability of clinical success.
- BCAX Bicara Therapeutics Watch
Balance sheet, trial, and M&A logic remain intact and PTAB institution improves the patent overhang picture, but efficacy case is still single-arm open-label and leadership bench will be substantially new by the time the interim prints.
-
Internal combo doublets now dosing in patients and cash runway intact through 2H catalyst window, but efficacy dataset is unchanged and the 2H 2026 readouts remain the binary test.
- NKTX Nkarta Watch
Q2 shows no efficacy data, faster burn, and a manufacturing footprint reduction, but outpatient dosing is now operational and cash still exceeds market cap; thesis intact pending H2 2026 readout.
- RLAY Relay Therapeutics Watch
The mechanism is de-risked and the chemistry is elite, but at ~$4.35B market cap the risk/reward has already been harvested on 57- and 20-patient open-label cohorts with managed denominators; revisit on the YE2026 vascular anomaly regulatory update or a ReDiscover-2 enrollment-completion announcement.
-
Both Alzheimer's catalysts pushed to Q4 2026, VY1706 first human safety data slipped to early 2027, ATM tapped into weakness at ~$3.61, and cash down to $148.8M; proxy waiting game extended.
-
Second IDMC pass at 80% exposure meaningfully reduces the safety tail and extends runway to Q1 2029, but the central PVR→6MWD scientific bet remains unresolved and the relaxin graveyard still demands humility ahead of the APEX binary.
-
Phase 3 initiation slipped from mid-2026 to upon IND clearance due to CMC manufacturing delays, funding language softened, and no efficacy readout is expected in the next twelve months; Watch List maintained with clock reset as the next event is an IND filing, not data.
- INMB Inmune Bio Watch
Q2 brought competent execution and improved catalyst clarity (US BLA now on calendar for Q1 2027) but neither named de-risker has landed — the going-concern flag remains and the MHRA MAA submission is still ahead — so the watch stance is maintained.
- INKT MiNK Therapeutics Watch
Encouraging early safety and biomarker data from C-1300-02 are positive but uncontrolled; the binary randomized readout has slipped to early 2027, adding two quarters of dilution risk with no change in the fundamental concerns that kept this off a Buy.
-
Watch List maintained as the CBP degrader IND timeline was withdrawn due to a CRO operational failure, weakening the wholly-owned pipeline leg, while FHD-909 remains a Lilly-controlled black box with no human efficacy data or readout date.
-
Term loan maturity pushed to 2029 removes the forced-financing cliff, but the cure thesis still rests on an unstarted NUC-withdrawal readout against an approvable competitor, keeping the stance on Watch List.
-
Cash fell to $45.1M, new FDRR language signals FDA dialogue is not converging, pipeline initiations are unfunded and overdue, but AbbVie option remains alive and burn discipline extends the optionality runway.
- ACET Adicet Bio Watch
Despite a de-risked mechanism and compelling early efficacy, the near-zero enterprise value, unreconciled enrollment language, and eGFR concerns in two of five LN patients make waiting for the 3Q/2026 22-patient readout the prudent call.
- PCVX Vaxcyte Watch
The Visp manufacturing suite is now certified for commercial operation, retiring one of four bear-case legs, but OPUS-1 must still clear a 0.667 noninferiority lower bound on 28 serotypes against two comparators with management-pre-announced misses, and the lot-to-lot study and ACIP remain unresolved.
- PALI Palisade Bio Watch
Prodrug engineering is real and balance sheet funds the binary, but PDE4 failed its one controlled UC trial, Phase 2 doses are below the regimen that generated the clinical signal, and there is no issued U.S. patent under a ~$457M market cap.
- NAMS NewAmsterdam Pharma Watch
Q2 update confirms balance sheet intact and EU approval advancing, but no U.S. NDA date disclosed and the single binary DSMB recommendation in Q1 2027 remains the only thing that matters for the U.S. thesis.
- TYRA Tyra Biosciences Watch
Second catalyst slip, ACH readout delayed a full quarter further behind infigratinib's NDA, burn running hotter, and stock already up 28% on no new efficacy data — asymmetry has narrowed; maintain Watch List ahead of September NMIBC CR readout.
- TGTX Tg Therapeutics Watch
Q2 beat and second guidance raise validate the commercial thesis, but at $46.17 — above the prior 52-week high — the easy entry has closed and the year-end SubQ Phase 3 topline remains the event worth sizing around.
- BEAM Beam Therapeutics Watch
Operational execution is tracking but LNP hepatotoxicity remains unproven at scale and the runway now leans on milestone-gated debt; the ERS late-breaking oral in September is a defined-event catalyst that may warrant only a starter position sized for a bad outcome.
- ANIX Anixa Biosciences Watch
FSHR biology is real but no objective response in four years, survival benchmark is misstated, and capital structure risks are material; wait for RECIST-confirmed responses from therapeutic-dose cohorts 5–7.
- ENTX Entera Bio Watch
Despite a de-risked mechanism and strong balance sheet post-financing, the 21-patient efficacy signal, untested Phase 3 dose, primary endpoint outside FDA's qualified 24-month context of use, and 85% post-financing markup into a 26-month catalyst desert make this the wrong entry at the wrong price.
- CGEN Compugen Watch
Near-cash EV with partnered Phase 3 royalty and Gilead option provides cushion, but the owned binary (COM701 monotherapy maintenance) rests on a post-hoc subgroup and thin single-agent data in a distrusted checkpoint class, warranting a watch rather than an immediate buy.
The full record
| Category | # calls | Beat XBI | Avg return | Avg vs XBI |
|---|---|---|---|---|
| Open buy calls | 129 | 37% | +17.8% | -4.9 |
| Core | 58 | 40% | +27.3% | -0.7 |
| Speculative | 71 | 35% | +10.1% | -8.3 |
| Open avoid calls | 18 | 94% | — | +24.6 |
| Closed buy calls | 17 | 24% | +12.5% | +1.2 |
| Closed avoids | 14 | 57% | — | -4 |
Hypothetical editorial track record, not a managed portfolio — past performance does not guarantee future results. Not investment advice.